180 related articles for article (PubMed ID: 31609933)
1. Combined Antiangiogenic Therapy and Immunotherapy Is Effective for Pancreatic Cancer With Mismatch Repair Proficiency but High Tumor Mutation Burden: A Case Report.
Chen M; Yang S; Fan L; Wu L; Chen R; Chang J; Hu J
Pancreas; 2019 Oct; 48(9):1232-1236. PubMed ID: 31609933
[TBL] [Abstract][Full Text] [Related]
2. Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy.
Giampieri R; Maccaroni E; Mandolesi A; Del Prete M; Andrikou K; Faloppi L; Bittoni A; Bianconi M; Scarpelli M; Bracci R; Scartozzi M; Cascinu S
Gastric Cancer; 2017 Jan; 20(1):156-163. PubMed ID: 26796888
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in pancreatic cancer and the importance of tumour testing.
Ngo P; Shanshal M; Rojan A
BMJ Case Rep; 2020 Jul; 13(7):. PubMed ID: 32675128
[TBL] [Abstract][Full Text] [Related]
4. Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy.
Viale G; Trapani D; Curigliano G
Biomed Res Int; 2017; 2017():4719194. PubMed ID: 28770222
[TBL] [Abstract][Full Text] [Related]
5. Microsatellite instability/mismatch repair deficiency in pancreatic cancers: the same or different?
Luchini C; Grant RC; Scarpa A; Gallinger S
Gut; 2021 Oct; 70(10):1809-1811. PubMed ID: 33468535
[No Abstract] [Full Text] [Related]
6. [Treatment of metastatic pancreatic cancer].
Heinemann V; Boeck S; Westphalen CB
Inn Med (Heidelb); 2022 Aug; 63(8):851-862. PubMed ID: 35925070
[TBL] [Abstract][Full Text] [Related]
7. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
[TBL] [Abstract][Full Text] [Related]
8. Durable benefit from immunotherapy and accompanied lupus erythematosus in pancreatic adenocarcinoma with DNA repair deficiency.
Pang X; Qian J; Jin H; Zhang L; Lin L; Wang Y; Lei Y; Zhou Z; Li M; Zhang H
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32636238
[TBL] [Abstract][Full Text] [Related]
9. Unexpected favorable outcome to sintilimab monotherapy in a relapse pancreatic ductal adenocarcinoma patient with high tumor mutational burden: a case report.
Zhang F; Li X; Liu H; Liu R; Zhou Z; Zhang Y; Chen J; Tian Y; Pan C; Meng Q; Liu Y
Anticancer Drugs; 2022 Oct; 33(9):975-978. PubMed ID: 35946538
[TBL] [Abstract][Full Text] [Related]
10. Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy.
Scilla KA; Bentzen SM; Lam VK; Mohindra P; Nichols EM; Vyfhuis MA; Bhooshan N; Feigenberg SJ; Edelman MJ; Feliciano JL
Oncologist; 2017 Jun; 22(6):737-742. PubMed ID: 28533476
[TBL] [Abstract][Full Text] [Related]
11. Germline variants in pancreatic cancer patients with a personal or family history of cancer fulfilling the revised Bethesda guidelines.
Ohmoto A; Morizane C; Kubo E; Takai E; Hosoi H; Sakamoto Y; Kondo S; Ueno H; Shimada K; Yachida S; Okusaka T
J Gastroenterol; 2018 Oct; 53(10):1159-1167. PubMed ID: 29667044
[TBL] [Abstract][Full Text] [Related]
12. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic ductal adenocarcinoma harboring microsatellite instability / DNA mismatch repair deficiency. Towards personalized medicine.
Lupinacci RM; Bachet JB; André T; Duval A; Svrcek M
Surg Oncol; 2019 Mar; 28():121-127. PubMed ID: 30851885
[TBL] [Abstract][Full Text] [Related]
14. Durable response after immune checkpoint inhibitor-related diabetes in mismatch repair-deficient pancreatic cancer.
Tsang ES; Walker EJ; Carnevale J; Fisher GA; Ko AH
Immunotherapy; 2021 Oct; 13(15):1249-1254. PubMed ID: 34338034
[TBL] [Abstract][Full Text] [Related]
15. Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions.
Lawlor RT; Mattiolo P; Mafficini A; Hong SM; Piredda ML; Taormina SV; Malleo G; Marchegiani G; Pea A; Salvia R; Kryklyva V; Shin JI; Brosens LA; Milella M; Scarpa A; Luchini C
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34206554
[TBL] [Abstract][Full Text] [Related]
16. Tumor mutation burden, DNA mismatch repair status and checkpoint immunotherapy markers in primary and relapsed malignant rhabdoid tumors.
Abro B; Kaushal M; Chen L; Wu R; Dehner LP; Pfeifer JD; He M
Pathol Res Pract; 2019 Jun; 215(6):152395. PubMed ID: 31047727
[TBL] [Abstract][Full Text] [Related]
17. Identification of germline genetic mutations in patients with pancreatic cancer.
Salo-Mullen EE; O'Reilly EM; Kelsen DP; Ashraf AM; Lowery MA; Yu KH; Reidy DL; Epstein AS; Lincoln A; Saldia A; Jacobs LM; Rau-Murthy R; Zhang L; Kurtz RC; Saltz L; Offit K; Robson ME; Stadler ZK
Cancer; 2015 Dec; 121(24):4382-8. PubMed ID: 26440929
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy holds the key to cancer treatment and prevention in constitutional mismatch repair deficiency (CMMRD) syndrome.
Westdorp H; Kolders S; Hoogerbrugge N; de Vries IJM; Jongmans MCJ; Schreibelt G
Cancer Lett; 2017 Sep; 403():159-164. PubMed ID: 28645564
[TBL] [Abstract][Full Text] [Related]
19. Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance.
Chen KH; Yuan CT; Tseng LH; Shun CT; Yeh KH
J Hematol Oncol; 2016 Mar; 9():29. PubMed ID: 27012666
[TBL] [Abstract][Full Text] [Related]
20. Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response.
Mandal R; Samstein RM; Lee KW; Havel JJ; Wang H; Krishna C; Sabio EY; Makarov V; Kuo F; Blecua P; Ramaswamy AT; Durham JN; Bartlett B; Ma X; Srivastava R; Middha S; Zehir A; Hechtman JF; Morris LG; Weinhold N; Riaz N; Le DT; Diaz LA; Chan TA
Science; 2019 May; 364(6439):485-491. PubMed ID: 31048490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
